Amgen (AMGN) Notes Payables (2009 - 2014)

Amgen has reported Notes Payables for 5 years, with the latest figure at $2.5 billion in Q1 2014.

• On a quarterly basis, Notes Payables rose 35685.71% year-over-year to $2.5 billion in Q1 2014; TTM through Mar 2014 was $2.5 billion, a 35685.71% increase from a year earlier, with the FY2013 full-year figure at $2.5 billion, changed 0.4% from the prior year.
• Notes Payables was $2.5 billion for Q1 2014 at Amgen, roughly flat from $2.5 billion in the prior quarter.
• The five-year high for Notes Payables was $2.5 billion in Q4 2013, with the low at $7.0 million in Q1 2013.
• Average Notes Payables over 4 years is $1.2 billion, with a median of $300.0 million recorded in 2011.
• The sharpest annual moves came in 2013 and 2014: Notes Payables plunged 99.55% in 2013, then surged 35685.71% in 2014.
• Over 4 years, Notes Payables stood at $84.0 million in 2011, then surged by 2870.24% to $2.5 billion in 2012, then rose by 0.4% to $2.5 billion in 2013, then changed by 0.0% to $2.5 billion in 2014.
• The last three Notes Payables figures came in at $2.5 billion (Q1 2014), $2.5 billion (Q4 2013), and $11.0 million (Q3 2013), per Business Quant data.